XML 95 R65.htm IDEA: XBRL DOCUMENT v3.22.4
Equity-Based Compensation - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Tax benefit realized from deductions to awards vested or exercised $ 2,100,000 $ 13,300,000 $ 2,700,000
Options      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Total fair value of options vested 126,000 76,000 223,000
Unrecognized compensation expense $ 433,000    
Expected to be recognized, weighted-average period 3 years 4 months 24 days    
Restricted Stock Units (RSUs)      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Expected to be recognized, weighted-average period 3 years    
Total compensation cost not yet recognized on grant date $ 94,800,000 $ 45,500,000 $ 34,500,000
Unrecognized compensation expense $ 110,600,000    
Restricted Stock Units (RSUs) | Fulgent Pharma Holdings      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Number of shares, granted 663,013